ABOUT MIB AGENTS

MISSION
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers through Programs, Education, and Research.

VISION
A world with less toxic, more effective treatments and a cure for osteosarcoma.

VALUES
We are devoted to creating and instilling hope with and for our inclusive and collaborative osteosarcoma community. We do this through mutual trust, transparency, and compassion.

To learn more about MIB Agents or to join the Mission, visit www.MIBagents.org or email info@mibagents.org

“We are so grateful for all your tireless and timely support to Jaden, our family, and others affected by osteosarcoma. Your unwavering effort and everything that MIB Agents is championing brings a lot of hope and comfort in difficult times. We are so grateful that we have found MIB and connect with you, a community we truly belong to.”

– Lei, Mother of Jaden
Dear Agents,

“...Any rational person would give up.” It seems this quote came from someone who retreated from civilization to a desert island to live a lonely and idle life. Most of us consider ourselves rational, yet against this metric, we are not - having not given up on causing a cure for osteosarcoma. Instead, we have collectively put our foot on the accelerator to speed toward improving a disease that is 77 million years old.

It has been an extraordinary journey since the start of MIB Agents and the six years since the first FACTOR conference in 2017. We have come together to support each other and the mission to Make It Better; by funding research in honor and in memory of those who have suffered and are suffering, by doing the research, and by sharing knowledge gained. You have generously and wholeheartedly shown up in all the ways; on OsteoBites weekly webinar and podcast, here at FACTOR, Mingle events, TURBO Tumor Board, contributing to OutSmarting research, welcoming us into your labs and institutions, and tirelessly working every day to cause a cure.

This work is equal parts humbling, heartbreaking, fulfilling, and inspiring. In this life, there are few things one can know for sure. One thing I know is that the only way we can improve this disease is together. Allow me to affirm that you are an essential ingredient in the secret sauce that is needed. Thank you for showing up, not just here but at the bench, and at the bedside, with and for kids who are suffering.

By the way, the full quote is “Without passion, any rational person would give up.” - Steve Jobs.

Thank you for your powerful, passionate and urgent obsession to Make It Better for kids with osteosarcoma. Welcome to San Diego! Let’s Cause A Cure!

With Hope,

Ann
Ann Graham
President & Osteosarcoma Survivor *(knock wood)*
MIB (Make It Better) Agents

---

**TABLE OF CONTENTS**

- MIB Mission ........................................... 1
- Conference Notes.................................. 3
- Agenda............................................. 4-6,8
- Wellness Agenda.................................. 7-8
- OsteoWarrior HQ Agenda.................... 9
- MIB Agents Family Funds............... 10-12
- FACTOR ’20 Photos ......................... 13-14
- Honoring our OsteoAngels............ 15-16
- Terms Glossary................................. 18
- Featured Art.................................... 18
- Speaker Bios.................................. 19-28
- Boards and Advisory ....................... 29
- Thank You..................................... 30
CONFERENCE NOTES

To make this conference as comfortable, safe, and productive as possible.

**MIB SPEAKER AGENT**
Check in with Christina Ip-Toma, MIB Director of Scientific Programs, to submit your thumb drive or for any questions with regard to your presentation.

**MIB FACTOR FLOOR MANAGER**
Questions for the Panel may be handed to Rob Marsh, who will present the questions to the Panel on your behalf, anonymously if you wish. If you’d like to ask your questions directly, please raise your hand for Rob to bring the microphone to you. During the session please be specific and brief.

**TIMELINE**
Our timeline is extremely tight. Kindly arrive a few minutes before the session start time to ensure the meeting can begin and end promptly.

**ETIQUETTE**
Kindly refrain from requesting medical advice or to review a specific case in this venue.

**NAME BADGES**
Please visibly display your badge throughout the conference.

**PHOTOGRAPHY AND VIDEO RECORDING**
The conference will be photographed and video recorded. Images may be used in MIB Agents promotional materials.

**ELECTRONICS**
Turn off or silence cell phones, PDAs, and electronic devices before each session begins.

**CHECK OUT**
If you plan on checking out on Saturday, please do so in the morning and store your luggage with the Bell Captain. This will avert any delay in your departure plans and avoid any late-check out fees.

**MIB AGENTS FACTOR SURVEY**
Please complete FACTOR survey to be passed out on Saturday afternoon and leave on the table at the end of conference. Your feedback helps us make improvements each year.

**COVID CONSIDERATIONS:**
It is of the utmost importance that we keep each other safe at the MIB FACTOR Conference. **If you are having symptoms including those associated with a cold or flu, we ask that you not attend - even if your test is negative.** Should you need to self-quarantine, we will provide you with a FACTOR Virtual Ticket at no additional charge. MIB Agents follows all state, county and resort guidelines regarding COVID-19 protocols and mask mandates.

**COMFORT LEVEL BUTTONS**
Please select a button during registration based on your comfort level and place it on your lanyard. We ask that you respect each individual’s level of comfort.

---

**CONFERENCES NOTES**

**LET’S WAVE + KEEP OUR DISTANCE**

**DOWN FOR A ELBOW/FISTBUMP**

**HERE FOR HUGS + HANDSHAKES**
AGENDA: THURSDAY, JUNE 23rd

12:00 - 6:00 PM
REGISTRATION OPENS
Located in the Loggia

5:00 - 6:00 PM
WELCOME RECEPTION
All registered FACTOR guests are welcome

5:15 - 5:30 PM
OSTEOWARRIOR VS. DOCTOR CHALLENGE
All registered FACTOR guests are welcome

6:00 PM
BUS DEPARTS FOR MIKE HESS BREWERY
Meet in the Lobby, all welcome

6:15 PM
SHUTTLE DEPARTURE FOR SPEAKER DINNER
Meet in the Lobby

6:45 - 8:45 PM
DINNER AT MIKE HESS BREWERY (NOT HOSTED)

6:45 - 8:45 PM
SPEAKER DINNER
By invitation only, off-site at Rosina’s Restaurant

8:45 PM
SHUTTLE RETURNS FROM MIKE HESS BREWERY
Traffic Dependant

8:45 PM
SHUTTLE RETURNS FROM SPEAKER DINNER

OsteoWarriors HQ Happenings
(page 9)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 - 7:45 AM</td>
<td>BREAKFAST AND REGISTRATION</td>
</tr>
<tr>
<td>8:00 - 8:10 AM</td>
<td>WELCOME AND OPENING REMARKS</td>
</tr>
<tr>
<td></td>
<td>Ann Graham, MIB Agents, Matteo Trucco, MD, MIB Agents, Cleveland Clinic</td>
</tr>
<tr>
<td>8:10 - 8:20 AM</td>
<td>PANEL INTRODUCTION: MIB AGENTS PROGRAMS</td>
</tr>
<tr>
<td></td>
<td>JUNIOR ADVISORY BOARD</td>
</tr>
<tr>
<td></td>
<td>Kara Skrubis, MIB Agents</td>
</tr>
<tr>
<td>8:20 - 8:30 AM</td>
<td>MIB AGENTS - PATIENT PROGRAMS</td>
</tr>
<tr>
<td></td>
<td>Isabel Wolf, MIB Agents</td>
</tr>
<tr>
<td>8:30 - 8:35 AM</td>
<td>MIB AGENTS - UPCOMING MIB EVENTS &amp; FUNDRAISING</td>
</tr>
<tr>
<td></td>
<td>Anita Caldera, MIB Agents</td>
</tr>
<tr>
<td>8:35 - 8:40 AM</td>
<td>MIB AGENTS - PARTNER PROGRAMS, FAMILY FUNDS</td>
</tr>
<tr>
<td></td>
<td>Teri-Gene Conlin, MIB Agents</td>
</tr>
<tr>
<td>8:40 - 8:50 AM</td>
<td>MIB AGENTS - SCIENTIFIC PROGRAMS</td>
</tr>
<tr>
<td></td>
<td>Christina Ip-Toma, MIB Agents</td>
</tr>
<tr>
<td>8:50 - 9:10 AM</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>9:10 - 9:25 AM</td>
<td>BREAK</td>
</tr>
<tr>
<td>9:25 - 9:35 AM</td>
<td>PANEL INTRODUCTION: TARGETED THERAPIES</td>
</tr>
<tr>
<td></td>
<td>Matt Murdoff, MIB Agents, Troy McEachron, PhD, NIH</td>
</tr>
<tr>
<td>9:35 - 9:45 AM</td>
<td>TOWARD PRECISION ONCOLOGY: LINKING CLINICAL AND - OMIC DATA IN PEDIATRIC OSTEOSARCOMA</td>
</tr>
<tr>
<td></td>
<td>Amanda Marinoff, MD, UCSF</td>
</tr>
<tr>
<td>9:45 - 9:55 AM</td>
<td>DEFINING NOVEL APPROACHES TO GENOME-INFORMED, TARGETED THERAPY FOR OS USING PATIENT-DERIVED XENOGRAFT MODELS</td>
</tr>
<tr>
<td></td>
<td>Alejandro Sweet-Cordero, MD, UCSF</td>
</tr>
<tr>
<td>9:55 - 10:05 AM</td>
<td>A DIFFERENT KIND OF PRECISION: TARGETING THE CELLS RESPONSIBLE FOR METASTASIS AND RECURRENCE</td>
</tr>
<tr>
<td></td>
<td>Ryan Roberts, MD, PhD, Nationwide Children's Hospital</td>
</tr>
<tr>
<td>10:05 - 10:15 AM</td>
<td>ATTACKING THE DIETARY BUILDING BLOCKS OF OSTEOSARCOMA</td>
</tr>
<tr>
<td></td>
<td>Brian Van Tine, MD, PhD, Washington University in St. Louis</td>
</tr>
<tr>
<td>10:15 - 10:35 AM</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>10:35 - 10:50 AM</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:50 - 11:00 AM</td>
<td>PANEL INTRODUCTION: LIQUID BIOPSIES AND BIOMARKERS</td>
</tr>
<tr>
<td></td>
<td>Max Penzer, MIB Agents, Alanna Church, MD, Boston Children's Hospital</td>
</tr>
<tr>
<td>11:00 - 11:10 AM</td>
<td>OPTIMIZING YOUR PATHOLOGY EXPERIENCE: BONE SARCOMAS</td>
</tr>
<tr>
<td></td>
<td>Jessica Davis, MD, Oregon Health &amp; Science University</td>
</tr>
<tr>
<td>11:10 - 11:20 AM</td>
<td>CIRCULATING TUMOR DNA AND CELLS IN OSTEOSARCOMA</td>
</tr>
<tr>
<td></td>
<td>Brian Crompton, MD, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>11:20 - 11:30 AM</td>
<td>OSTEOSARCOMA LIQUID BIOPSY, THE NPCF MULTI-CENTER TRIAL EXPERIENCE</td>
</tr>
<tr>
<td></td>
<td>Masanori Hayashi, MD, University of Colorado</td>
</tr>
<tr>
<td>11:30 - 11:40 AM</td>
<td>THE TRANSLATIONAL POTENTIAL OF GENOMIC PROFILING VIA TUMOR AND LIQUID BIOPSY ANALYSIS IN CANINE OS</td>
</tr>
<tr>
<td></td>
<td>Brian Flesner, DVM, MSc, University of Pennsylvania</td>
</tr>
<tr>
<td>11:40 - 12:00 PM</td>
<td>PANEL DISCUSSION</td>
</tr>
</tbody>
</table>

You can also view the Agenda and Speakers List by visiting: www.MIBAgents.swoogo.com/factor2022/
### AGENDA: SATURDAY, JUNE 25th

#### 6:45 - 7:45 AM
**BREAKFAST AND REGISTRATION**

#### 8:00 - 8:10 AM
**PANEL INTRODUCTION: IMMUNOTHERAPIES**

- **Ally Tamayose**, MIB Agents
- **Alex Huang, MD, PhD**, UH Rainbow Babies & Children’s Hospital / Case Western Reserve University School of Medicine

#### 8:10 - 8:20 AM
**TARGETING STING/ENPP1 TO REPROGRAM AN IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT IN OS**

- **Betsy Young, MD**, UCSF Benioff Children’s Hospital

#### 8:20 - 8:30 AM
**AEROSOLIZED GEMCITABINE MODULATES THE OSTEOSARCOMA TUMOR MICROENVIRONMENT AND INCREASES NATURAL KILLER CELL EFFICACY**

- **Ariana Anjier, MS**, UT MD Anderson Cancer Center

#### 8:30 - 8:40 AM
**TARGETING CD70 USING CAR-NK CELLS TO ENHANCE NK CELLS CYTOTOXIC EFFECT AGAINST OSTEOSARCOMA**

- **Emily Rav, DO**, University Hospitals/Rainbow Babies & Children’s Hospital

#### 8:40 - 8:50 AM
**USING RNA-NANOPARTICLE VACCINES TO OVERCOME THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF METASTATIC OSTEOSARCOMA**

- **John Ligon, MD**, University of Florida

#### 8:50 - 9:00 AM
**MODULATING TGF-BETA SIGNALING IN THE TUMOR MICROENVIRONMENT AS AN EFFECTIVE THERAPY FOR OS**

- **Kristen VanHeyst, DO**, University Hospitals/Rainbow Babies & Children’s Hospital

#### 9:00 - 9:10 AM
**THE ORALLY BIOAVAILABLE STAT3 INHIBITOR WP1066 AS A NOVEL THERAPEUTIC APPROACH AGAINST OSTEOSARCOMA- LUNG METASTASES**

- **Pradeep Shrestha, PhD**, The UT MD Anderson Cancer Center

#### 9:10 - 9:30 AM
**PANEL DISCUSSION**

#### 9:30 - 9:45 AM
**BREAK**

#### 9:45 - 10:00 AM
**OSTEOSARCOMA INSTITUTE**

- **Lee Helman, MD**, Osteosarcoma Institute

#### 10:00 - 10:40 AM
**2022 OUTSMARTING OSTEOSARCOMA FUNDED RESEARCH**

#### 10:40 - 10:55 AM
**BREAK**

#### 10:55 - 11:10 AM
**PANEL INTRODUCTION: LOCAL CONTROL**

- **Elise Robinson, MIB Agents**
- **Jane Yanagawa, MD**, UCLA

#### 11:10 - 11:20 AM
**THE PROGNOSTIC SIGNIFICANCE OF LYMPHOVASCULAR TUMOR INVASION IN LOCALIZED HIGH-GRADE OSTEOSARCOMA: OUTCOMES OF A SINGLE INSTITUTION OVER TEN YEARS**

- **Alan Blank, MD, MS**, Rush University Cancer Center

#### 11:20 - 11:30 AM
**EVOLUTION OF RADIATION TREATMENT PARADIGMS FOR PEDIATRIC AND AYA SARCOMAS**

- **Stephanie Terezakis, MD**, University of Minnesota

#### 11:30 - 11:40 AM
**A NOVEL LRRC15-TARGETED RADIOTHERANOSTIC MODALITY FOR OSTEOSARCOMA**

- **David Ulmert, MD, PhD**, UCLA

#### 11:40 AM - 12:00 PM
**PANEL DISCUSSION**

#### 12:00 - 1:00 PM
**LUNCH**

- **Saturday Lunch sponsored by OS Collaborative**

#### 1:00 - 1:10 PM
**PANEL INTRODUCTION: IMPROVING EXISTING THERAPIES**

- **Vicky Hoy, MIB Agents**
- **Leo Mascarenhas, MD, MS**, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California

#### 1:10 - 1:20 PM
**MAXIMIZING SAFETY, EFFICACY AND TOLERABILITY: THE USE OF LIPOSOMAL DOXORUBICIN IN CHILDREN, ADOLESCENTS & YOUNG ADULTS WITH ADVANCED SARCOMA**

- **Stacey Zahler, DO**, Cleveland Clinic Children’s

#### 1:20 - 1:30 PM
**GLUCARPIDASE USE IN 86 PEDIATRIC AND YOUNG ADULT PATIENTS RECEIVING HIGH-DOSE METHOTREXATE THERAPY: POOLED SUBGROUP OF ANALYSIS OF OPEN-LABEL TRIALS**

- **Katie Janeway, MD**, Dana-Farber Cancer Institute

#### 1:30 - 1:40 PM
**TOWARD RAPID DEVELOPMENT OF A CURE FOR OS USING A TWO-DRUG COMBINATION OF REPURPOSED DRUGS, DIRECTLY TO PH II WITH POTENTIAL ACCELERATED FDA APPROVAL**

- **Scott Sauer, PhD**, Viva De Sciences

#### 1:40 - 1:50 PM
**EVALUATING THE ROLE OF HYALURONAN IN OSTEOSARCOMA PULMONARY METASTASES**

- **Emily Pope, DVM/PhD Candidate**, University of Minnesota

#### 1:50 - 2:10 AM
**PANEL DISCUSSION**

#### 2:10 - 2:25 AM
**BREAK**

#### 2:25 - 2:35 PM
**PANEL INTRODUCTION: CLINICAL TRIALS**

- **Carrigan Nelson, MIB Agents**
- **Michael Isakoff, MD**, Connecticut Children’s Medical Center

#### 2:35 - 2:45 PM
**A PHASE 1/2 STUDY OF ZN-C3, WEE1 INHIBITOR, PLUS GEMCITABINE IN RELAPSED OR REFRACTORY OSTEOSARCOMA**

- **Vishu Avutu, MD**, Memorial Sloan Kettering Cancer Center

#### 2:45 - 2:55 PM
**SARCO38: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA**

- **Lara Davis, MD**, Oregon Health & Science University

#### 2:55 - 3:05 PM
**A PROSPECTIVE, NATIONAL STUDY OF ADJUVANT HER2-EXPRESSING LISTERIA IN DOGS WITH OSTEOSARCOMA**

- **Nicola Mason, BVetMed, PhD**, University of Pennsylvania

#### 3:05 - 3:15 PM
**NEXT GENERATION CELL THERAPY FOR OSTEOSARCOMA**

- **Rosie Kaplan, MD, NIH**

#### 3:15 - 3:30 PM
**BREAK**

#### 3:30 - 3:40 PM
**STRIKE AND ENLIGHTEN: SOLID TUMOR CAR T CELL THERAPY FROM SEATTLE CHILDREN’S THERAPEUTICS**

- **Katie Albert, MD**, Seattle Children’s Therapeutics

#### 3:40 - 3:50 PM
**HARNESSING NATURAL KILLER CELLS FOR THE TREATMENT OF OS BHUVANAN SETTY, MD, Nationwide Children’s Hospital**

#### 3:50 - 4:00 PM
**CHILDREN’S ONCOLOGY GROUP TRIALS FOR OSTEOSARCOMA**

- **Katie Janeway, MD, MMSc**, Dana-Farber Cancer Institute

#### 4:00 - 4:30 PM
**PANEL DISCUSSION**

#### 4:30 - 4:35 PM
**INTRODUCTION TO CLOSING REMARKS**

- **Matthew Allen, MIB Agents**

#### 4:35 - 4:50 PM
**CLOSING REMARKS**

- **Alexis Johnson, MIB Agents**

#### 4:50 - 5:00 PM
**GOODBYE**

- **Ann Graham, MIB Agents**
- **Matteo Trucco, MD**, Cleveland Clinic, MIB Agents
WELLNESS TRACK: FRIDAY, JUNE 24th

Wellness Track events are complimentary for all registered FACTOR guests.

9:35 - 10:35 AM

**CHOOSE A WELLNESS PATH**

- **WELLNESS WALK**
  - Tyler Strickland

**OR**

- **MAGNIFICENT MATISSE PAINTING CLASS**
  - Sarah Hanna

10:35 - 11:00 AM

**BREAK**

11:00 AM - 12:10 PM

**CHOOSE A WELLNESS PATH**

- **CHAIR STRETCH**
  - Tyler Strickland

**OR**

- **MAGNIFICENT MATISSE PAINTING CLASS**
  - Sarah Hanna

12:00 - 1:00 PM

**LUNCH**

1:00 - 1:20 PM

**GROUP PHOTO**

1:30 - 2:40 PM

**CHOOSE A WELLNESS PATH**

- **WELLNESS WALK**
  - Tyler Strickland

**OR**

- **TASTE OF THIEBAUD PAINTING CLASS**
  - Sarah Hanna

2:40 - 2:55 PM

**BREAK**

2:55 PM - 4:25 PM

**CHOOSE A WELLNESS PATH**

- **INTENTIONAL COLLAGE**
  - Serena Sandino

**OR**

- **TASTE OF THIEBAUD PAINTING CLASS**
  - Sarah Hanna

---

Tag all FACTOR Conference social media posts with the hashtags

#CAUSEACURE #FACTOR22

---

**Tyler Strickland**

Fitness Specialist
Training With Tyler LLC

**Serena Sandino**

Full time cancer mom and empath

**Sarah Hanna**

Fine Art & Painting Atelier
SarahHanna.com

**Lisa Thompson, RN**

Healing Touch, Massage Therapy
Rady Children’s Hospital San Diego

**Tedd Kapinos**

Founder/Owner
Jasper & Prudence
Floral and Events
www.jasperandprudence.com
**WELLNESS TRACK: SATURDAY, JUNE 25th**

**Laura Dunlop & Jake Morton**
Professional Dancer & Pilates Master Trainer
Pure Energy Pilates
@pureenergypilates on instagram

**Jeanie Spies, NP**
Integrative Medicine Program Coordinator; Peckham Center Nurse Practitioner
Rady Children’s Hospital San Diego

**Jeny Dawson**
Zen Soul Balance
www.zensoulbalance.com

**JoAnne Auger, RN, CHPPN**
Supportive Care RN Coordinator
Rady Children’s Hospital San Diego

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30 AM</td>
<td>MADE FRESH DAILY Rancho Bernardo Spa Therapist</td>
</tr>
<tr>
<td>9:30 - 9:45 AM</td>
<td>BREAK</td>
</tr>
<tr>
<td>9:45 - 10:40 AM</td>
<td>CHOOSE A WELLNESS PATH</td>
</tr>
<tr>
<td>10:40 - 10:50 AM</td>
<td>BREAK</td>
</tr>
<tr>
<td>11:00 AM - 12:10 PM</td>
<td>CHOOSE A WELLNESS PATH</td>
</tr>
</tbody>
</table>

**SUNDAY, JUNE 26th**

**Healing Hearts Grief Retreat “Bonding Thru The Five Senses”**

We will explore using our senses to take care of ourselves, to build protective factors and to regulate our nervous system, especially in connection to our grief. Finding ways not only of comfort, but to keep us connected to our loved one. During the workshop portion of the retreat, we will explore new ways to continue bonding with our loved one and stay connected to them.

After the workshop we will gather as a group for the opportunity to openly express and share with our peers. Join us to share with and support others who have the experience and understanding of what it is like to lose a child through osteosarcoma. Please bring a copy of a photo of your child to the retreat.
OSTEOWARRIOR HEADQUARTERS (HQ)

OsteoWarriors and Siblings ages 18 and under can attend HQ located at Granada near the lobby.

THURSDAY, JUNE 23rd

4:00 PM
HQ OPENS
Granada

4:15 - 5:00 PM
SCAVENGER HUNT
Meet in HQ

5:15 - 5:30 PM
WARRIORS VS. DOCS FOR THE GOLDEN BONE
North Lawn

6:15 - 9:15 PM
TACOS AND CRAFT ROOTBEER AT MIKE HESS BREWING
Meet in Lobby at 6PM for transportation

10:00 PM
HQ CLOSES

FRIDAY, JUNE 24th

8:00 AM
HQ OPENS & CONTINENTAL BREAKFAST
Everyone is welcome to join all attendees for breakfast on Bernardo Patio from 6:45-7:50 AM. For those who wish to sleep in, light breakfast will be available in HQ.

8:30 - 9:30 AM
HQ HANGOUT - GAMING, CARDS, ROCK PAINTING

10:00 AM
BUS LEAVES FOR SAN DIEGO SAFARI PARK

5:15 - 5:30 PM
BUS TO DEPART SAFARI PARK

6:00 - 6:30 PM
DINNER AT IN-N-OUT BURGER

6:30 - 7:00 PM
BUS RETURNS

7:00 - 10:00 PM
HQ HANGOUT

SATURDAY, JUNE 25th

8:00 - 9:00 AM
CONTINENTAL BREAKFAST

8:30 - 9:30 AM
OPEN PAINTING STUDIO
With Sarah Hanna

9:30 - 9:45 AM
SNACK (WITH OTHER ATTENDEES)

10:00 AM - 12:00 PM
PICASSO PORTRAIT PAINTING
With Sarah Hanna

12:20 - 3:00 PM
POOL PARTY WITH LUNCH
Family Pool with Lunch on Granada Lawn

3:30 - 5:30 PM
WONDERFUL WARHOL PAINTING CLASS
With Sarah Hanna
HAIR & MAKEUP
WARRIOR & FAMILY PHOTOS

5:00 PM
END OF CONFERENCE

5:30 PM
HQ CLOSES

Join Gamer Agents during HQ hours for video gaming!

---

St. Baldrick’s Foundation
Conquer Childhood Cancers
In honor and memory of their children, Family Funds raise money to Make It Better for kids and young adults with osteosarcoma. Their efforts fund desperately needed osteosarcoma research, educational resources, and programs that support kids and families in treatment. Family Funds have an opportunity to co-brand research grants and provide valuable patient perspective during our grant review process.

To learn more about a Family Fund, simply take a photo of QR code with your phone.
SETTING UP AN MIB AGENTS FAMILY FUND

What is a Family Fund?
Family Funds honor a child in treatment or the memory of a child who passed from osteosarcoma. Their efforts fund desperately needed osteosarcoma research, educational resources, and programs that support kids and families in treatment.

How Does MIB Agents Help Me Honor My Loved One?
Family Fund honorees are on our website always with a personal page for each honoree’s story. In addition, we share their stories on our website, social media (at least 2x/year), at our FACTOR and FACTORx conferences and other MIB events throughout the year.

Family Funds have an opportunity to co-brand Outsmarting Osteosarcoma research grants and provide valuable patient perspective during our grant review process. Thanks to MIB Family Funds we are able to award $450,000 in 2022!

How Do I Set Up My Family Fund?
It is easy to get your Family Fund set up. Visit www.mibagents.org/about-family-funds to learn more about how to get a Family Fund started. You may also email Teri-Gene, Director of Development teri-gene@mibagents.org, or find her at the conference for more information.

Family Funds are an essential part of the mission of MIB Agents to Making It Better for those facing osteosarcoma. Please consider being part of this important program.

MIB AGENTS FAMILY FUND
FACTOR TRAVEL AWARD

The MIB Agent Family Fund FACTOR Travel Award is supported by MIB Agents Family Funds who raise funds in honor of their OsteoWarrior or OsteoAngel. Their dedication to Making It Better and fostering collaboration and education in the scientific community makes every MIB Agents award incredibly meaningful. The Family Fund FACTOR Travel Award ensures researchers/doctors can attend FACTOR if they don’t have institution or grant support.

Bisaga Family #BecauseOfAndrew
Grilo Family #BecauseOfAnnaleigh
Gabster & Peterson Family #BecauseOfBrooke
Murfod Family #BecauseOfCharlotte
Toma Family #BecauseOfDylan
Crossan Family #BecauseOfConner
Klok Family #BecauseOfGavin

Greene Family #BecauseOfIan
Egan Family #BecauseOfKyle
Lehrman Family #BecauseOfMatthew
Kaplan Family #BecauseOfSydney
Marsh Family #BecauseOfVictoria
Holmes Family #BecauseOfMegan

“The FACTOR Conference is unique in that it brings together parents, patient advocates, providers, the scientific community and others to share common issues and research advances, and to remember our common struggles against osteosarcoma.”

–Richard Gorlick, MD

“Our deep gratitude to Jasper & Prudence for their ongoing support of MIB Agents and our missions all year long, and for making our FACTOR Conference beautiful every year!”

JASPER & PRUDENCE
FLORAL AND EVENTS
802.952.8909 | 617.417.4965
jasperandprudence.com
Brock Gumm
Brianna Sanchez
Brianna Gainley
Briana Loeding
Brian George
Brennan Riley
Brent Ramer
Brenton
Brenna Loeding
Brianna Gainley
Brianna Sanchez
Brook Gunn
Brooke Foster
Brooke Gabster
Brooks Paul
Calin Capri Cannella
Cali Sky Weihsaup
Cameron Bottebergh
Cameron Orellana
Carlo Minasi
Carson Sumpter
Caroline Richards
Carson Hartwig
Carson Michael Lewis
Carson Sumer
Carter Mock
Catherine Kelly
Cecilia Nguyen
Cem Yelmen
Chance Rodgers
Charlotte Murdoff
Chase Bailey
Chelsea Ebert
Chayenne Develasco
Chris Hailey
Chris Taylor
Christie Hanovnikian
Christien Mikhail Quiles
Claire Moody
Clayton
Colleen Moore
Collin Rives
Colton Kuepfer
Connor Crossan
Cullen Klefsis
Damon “Super D” Billeck
Dan Kenneavy
Daniel Garcia-Beech
Daniel Stanley
Darien King
Darren Vink
David Jacobsohn
David Gulko
David Padilla
David Robbins
Desiree Ericka
Devon Currie
Devon Dinkens
Dominic Whittmann
Doug Brown
Drew Thomas Martin
Drew Hillard
Dustin Smith
Dylan McCabe
Dylan Toma
Dylan McCormack
Earl Cook
Elijah Alemian
Emily Del Vecchio
Emma Koertzen
Emmanuel Kwan Y Acemang
Ethan Fox
Eve Eriksen Richards
Faith Fulmer
Fiona Morris
Gabriel Taylor
Gabriella Castillo
Garland Chase Bailey
Garrett Harper
Gavin McClain
George Bertolli
Gina Lynne Schell
Grant McGarry
Greg Von Rueden
Gordon Shields
Hallie Anne Sowers
Hayden Perry
Heidi Tolo Merkle
Heath Sammon
Hunter Spradlin
Hunter Spurgeon
Ian Greene
Ian Vallejo
Isaac Smith
Jack Hysner
Jackson Roark
Jacob Malay
Jake Cavanaugh
James Hayden
James McCullum
James Schwering
James Ragan
Jana Wang
Janina Vargas
Jared
Jared Hollingsworth
Jayden Isaiah Ojeda
Jayden Thompson
Jaylen Winzer
Jayme Ax
Jeremy Telling
Joe Friend
Joern Wistes Andersen
John Gibbons – brother
Jonah Christian
Jonathan E Faure
Jordan Baysinger
Jordan Jacques
Jordan Wright
Jorge Strong (Jorge Ibanez)
Jori Zemel
Josh Deaton
Josh Hardley
Joshua Williamson
JR Burnett
Justin Coven
Justin Spika
Kaitlyn Bernhardt
Kali Peter
KarmaMaestas
Katherine Ewing
Katie Elliot
Katie Roger
Katie Wilson
Kaycee Ann Chester
Keaton Lee McMurray
Keegan Fletcher
Kelle Lucas
Kellin
Kernir Angelo Gonzales
Vergha
Kennedy Griffith
Kenny Moffitt
Kyle Ashley
Kyle Brustowicz
Kyle Patrick Egan
Kyle Miller
Kyra Root
Lance Hussfeldt
Lance Cooper
Laura Stewart
Lauren Moody
Lauren Smith
Leath Chelsky
Lena (Denmark)
Lena Leonard
Leon Huhn
Levis Bryant Jr.
Liberty Nicole Bell
Liddy Shivver
Lily Anderson
Lindsey Wilkins
Lisa Harder
Liz Rowan
Logan Boyd
Luke LaPray
Luke LaRae
Luke Simons
Madi Graham
Mackenzie Kenzi Larson
Maddie Lane Demers
Madeline Parker Higgins
Malcolm Hill
Manny Lopez
Marc Nieuwborg
Marcia Westall
Marilyn Delgado
Marshall Robert Fisher
Marshall Smith
Mason Wilson
Mason Chandler Allen
Mathias Giordano
Matt Clevenger
Matthew Lehrman
Matt Siegel
Mattie Brown
Mckenna Rae Schummer
Megan Holmes
Megan Sheehy
Michael Heras
Michael “Tank” Pacheco
Mikayla Rose Adams
Miranda Ram-Nolte
Mitchell Koltz
Miya Norse
Mohan Anand
Molly
Morgan Anderson
Muriel Walters
Mwai
Naia Symone McCutchin
Natalie Hill
Nathan Noel Burgess
Nathan Silpath
Nick Wichman
Nick Widner
Nazar
Nicholas Reamer
Nicholas Floyd
Nicholas Kroeger
Nicholas Reamer
Nick Mendez
Nikki Jenkins
Noah Caceras
Noah Nieto
Oliver Feldman
Olivia “Livy” Lear
Owen Wicks
Paul Barker
Patrick Battle Jr.
Patrick James Fridland
Patricia Collett
Randy Bultena
Raul Buehas
Rayjay Verdi
Reni Ratio
Rick Sattele
Robert Robbie Mudroch
Ronald Abidog
Rory Zimm
Ryan Tierny
Ryan Tobin
Sabrina Mariottu
Safnamoli Yossa
Salote Lauti
Sam Bish
Sam Merkel
Samantha Ashburn
Sammie Hartfield
Samuel Holmes
Sara Corbelli
Sarah Maria Brauser Hays
Sarah Swensen
Scott Shockley
Seth Bombert
Seth H. Brooks
Seth Wright
Shane Christensen
Shane Schuster
Shannon Casey
Shannon Wilkes
Sharon Roloff
Shayla Holwegner
Sheryl Lunde
Sid Orton
Sierra Hibge
Soren Fairburn
Soren Vestergaard
Steve Kmit
Steven England
Sydney Kaplan
Tanner
Tashayla “Shay” Clayton
Tate Michek
Tawnya Phillips
Tim Klotz
Tucker Judith Helstrom
Todd Andrews
Tom McCaulley
Travis White
Tyler Baker
Tyler Keeton
Tyler Musselwhite
Victor “Tito” Morales
Wenwen Chen
Will Krajewski
Will Mohr
William Birdsell
William Maki
Willie Tichenor
Zach Irelan
Zach Sobiech
Zack Sochor
Zane Jacobsen
Ziggy
We are on a mission to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science.

OSI has funded:
10 Awarded Grants | $3.8+ Million
Clinical Trials | Correlative Science | Translational Research

Join us in concentrating on the cure by:

- Learning About Our Funded Work
- Meeting OSI’s Strategic Advisory Board
- Reviewing Research Grant Opportunities
- Exploring Patient Resources
- Reading Inspirational Osteosarcoma Stories

OSI Connect

OSI Connect is a free resource linking patients, families, and caregivers with knowledgeable osteosarcoma expert physicians to answer questions about all aspects of the disease. Se habla español.

OSI Connect can discuss:
1) available treatments and possible side effects
2) further benefiting from visits with your care team
3) helpful resources and/or additional information

Scan the QR code to learn more about OSI!
Sarah is a visual artist and professional arts educator who has (for the past 22 years) taught fantastic, creative students from her studios in California, Florida and the French Riviera. In 2020, Sarah created her Art In Residence program - an in-home family painting experience that blends joy and experience on enormous canvases. She travels coast-to-coast to work with families of aspiring artists.

Website: www.sarahhanna.com
Instagram: @artfulcorrespondence
FACTOR 2022 PRESENTERS

Catherine (Katie) Albert, MD
Attending Physician, Assistant Professor
Seattle Children's Research Institute

Dr. Albert is an attending physician at Seattle Children's Hospital and Assistant Professor of Pediatrics at the University of Washington School of Medicine. She is the medical director of the Solid Tumor Program at SCH and her clinical focus is pediatric and young adult sarcomas. Her research is focused on finding more effective therapies for high risk sarcomas, with a focus on adoptive cellular therapies.

Ariana Anjier, MS
Senior Research Assistant
University of Texas MD Anderson Cancer Center

Ariana is completing her PhD this year and has a background in comparative anatomy and physiology. She joined Dr. Nancy Gordon's lab two years ago and is currently investigating the use of low-dose aerosolized gemcitabine to improve NK cell therapy in lung metastases in preclinical animal models.

Viswatej (Vishu) Avutu, MD
Assistant Attending
Memorial Sloan Kettering Cancer Center

Dr. Vishu Avutu attained his M.D. from the University of Texas Southwestern Medical School and began his research endeavors with the Pediatric Oncology Education Program at St. Jude Children's Research Hospital; finding a passion for working with adolescents and young adults, Vishu matched to the internal medicine-pediatric residency at Harvard's Brigham and Women's/Boston Children's Hospitals. In addition to serving as Chief Resident, Vishu helped develop and launch the Center for Adolescent and Young Adult Oncology at the Dana Farber Cancer Institute. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a co-founder of MSK's Adolescent and Young Adult Oncology Program, where his work has garnered MSK's Patient and Family Centered Care Grant Initiative and the Young Investigator Award from the American Society of Clinical Oncology. He is an assistant attending in the Departments of Medicine and Pediatrics and cares for AYAs with sarcomas.

Christina Baker, PhD
Pediatric Psychologist
Rady Children's Hospital

Christina Baker is a pediatric psychologist in the hematology/oncology department of Rady Children's Hospital, San Diego. She assists children, teens, young adults, and their families in adjustment to diagnosis and treatment. Clinically, Christina focuses on age-appropriate communication of health-related information, affective and behavioral concern monitoring, education and coaching on adaptive cognitive/behavioral coping strategies, behavioral modification strategies, and grief counseling. Christina also participates in various research projects, anticipating several publications in the near future. In her short time with Rady Children's, she has assisted in creation of several various support groups and a practicum training program.

Alan Blank, MD, MS
Assistant Professor
Rush University Cancer Center

Dr. Blank is an orthopedic oncologist at Rush cancer center specializing in the treatment of malignant and benign musculoskeletal tumors. He completed his residency at NYU followed by a cancer fellowship at the Huntsman Cancer Institute. In addition to having a strong passion for clinical care, he also runs a very active sarcoma research group.

Anita Caldera
Fundraising Events Manager
MIB Agents

Anita Caldera recently joined MIB as Fundraising Events Manager. She has worked in the non-profit space for over 10 years, leading with compassion and advocating for families navigating Early Intervention Program and most recently with the National Hemophilia Foundation executing small to mid-scale events. She is passionate about wellness, building relationships, and is already Making It Better alongside the MIB Team, our community of patients, caregivers, doctors and researchers.
Dr. Church is a board-certified Pediatric Pathologist and Molecular Genetic Pathologist. She is the Associate Director of the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children's Hospital, and an Assistant Professor at Harvard Medical School. She has participated in several high-impact studies using molecular profiling for pediatric cancers, including the iCat study, Profile study, and the ongoing multi-institutional GAIN consortium study. Her career is dedicated to implementing high-quality accessible molecular profiling tests to support the care of children with cancer.

Dr. Crompton is a pediatric oncologist and physician scientist at Dana-Farber/Boston Children's Cancer and Blood Disorder Center. His research focuses on utilizing genomic and proteomic technologies to identify and validate new therapeutic targets for pediatric solid tumors and to develop non-invasive biomarkers of treatment response and resistance in these diseases. His laboratory has developed new approaches to estimating circulating tumor DNA (ctDNA) levels from liquid biopsy samples from patients with pediatric solid tumors. These assays help track ctDNA levels over time and allow correlation between ctDNA levels and response to therapy and outcome. His team is also developing strategies for identification, quantification, and interrogation of circulating tumor cells (CTCs) from liquid biopsy samples, including the application of single-cell profiling technologies.

Dr. Lara Davis is an Associate Professor at Oregon Health & Science University (OHSU), where she is the Sarcoma Program Director and co-leads the Translational Oncology Program of the Knight Cancer Institute. She completed combined training in Medical Oncology and Pediatric Hematology/Oncology in order to pursue a career in adolescent and young adult sarcoma care. Dr. Davis runs a number of clinical trials, including SARC038, a phase 2 trial of nivolumab and regorafenib for osteosarcoma, which she co-leads with Dr. Fariba Navid of CHLA. In addition, Dr. Davis directs translational osteosarcoma research at the Knight Cancer Institute's Center for Experimental Therapeutics. She is the recipient of an NCI Cancer Clinical Investigator Team Leadership Award as well as career development awards from SARC and the St. Baldrick's Foundation.

Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a incredibly comprehensive and multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. Dr. Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
“Having foundation support allows us the assurance that we have the funding necessary to keep going. It’s critical.”

– Alex Huang, MD, PhD
Lee Helman, MD
Director
Osteosarcoma Institute

Dr. Helman received his MD from the University of Maryland School of Medicine, magna cum laude. He completed his internship/residency in internal medicine at Barnes Hospital, Washington Univ. & trained in medical oncology at the National Cancer Institute (NCI). He is board certified in internal medicine/medical oncology. He did his postdoctoral training in the Molecular Genetics Section, Pediatric Branch & then became Head of the Molecular Oncology Section, Pediatric Oncology Branch (POB). He served as POB Chief & Scientific Director for Clinical Research in the Center for Cancer Research. These positions were all at NCI. He then joined Children’s Hospital Los Angeles/USC’s Keck School of Medicine as professor of Pediatrics & Medicine, and director of Basic and Translational Research within the Children’s Center for Cancer & Blood Diseases. He serves as a vice-chair of the Scientific Advisory Committee of Stand Up To Cancer and is currently the Director of the Osteosarcoma Institute.

Alex Huang, MD, PhD
Professor of Pediatrics; Director, Center for Pediatric Immunology
UH Rainbow Babies & Children’s Hospital / Case Western Reserve University School of Medicine

Alex Huang is a pediatric oncology physician-scientist with an active basic and translational research program focused on cellular and molecular immunology and immuno-oncology. His team’s research has focused on defining vulnerabilities within the osteosarcoma tumor microenvironment that can be translated into clinical trials in the next few years. They’ve already opened the Natalizumab trial (NCT03811886) targeting un-resectable pulmonary osteosarcoma, and are working on opening several other clinical trials targeting refractory, metastatic and recurrent osteosarcoma.

Katie Janeway, MD, MMSc
Director, Clinical Genomics
Dana-Farber Cancer Institute

Dr. Janeway’s prior work has uncovered genomic events underlying difficult-to-treat childhood solid malignancies. She has leveraged this understanding to expand treatment opportunities and improve clinical trials for children with advanced childhood solid malignancies. Her research group is currently focused on better characterizing the clinical impact of genomic sequencing. A major project in the laboratory addressing this question is the iCat2/GAIN consortium study which has enrolled and sequenced over 500 patients with difficult-to-treat childhood solid cancers. Her group is also involved in efforts to share and aggregate both sequencing and clinical data to enable a deeper understanding of childhood cancers. They have several data generation and sharing projects aiming to better characterize the genomics of osteosarcoma and Ewing sarcoma. With these projects they hope to identify clinic genomic factors explaining prognosis and treatment response and resistance.

Christina Ip-Toma
Director of Scientific Programs
MIB Agents

Christina’s son Dylan was diagnosed with osteosarcoma in 2016. They attended the first MIB Agents FACTOR conference in 2017 and found a tremendous community of support and helpful resources. Dylan bonded with fellow OsteoWarriors at Warrior HQ at FACTOR every year while Christina and Dylan’s dad Burt soaked up all the information they could from FACTOR scientific sessions and other MIB Agents resources like OsteoBites. As a volunteer Agent, Christina worked with a team of OsteoMoms and doctors to create the MIB Agents Testing and Research Directory in 2019. When Dylan passed away in 2021 after bravely battling osteosarcoma for five years, Christina joined the MIB Agents team in January 2022 as the Director of Scientific Programs. In this role, Christina creates programs to engage and support the scientific community who are striving to improve treatment options and outcomes. In addition to being a proud owner of a MIB Agents Family Fund honoring Dylan, she is also a founding member of the Battle Osteosarcoma team that partnered with St. Baldrick’s Foundation to fund a $1.4 million research grant, and a consumer reviewer for the CDMRP Peer Review Cancer Research Program. She is grateful to MIB Agents for giving her the opportunity to make it better for OsteoWarriors everywhere, which is helping her transform senseless loss into a sense of purpose - #BecauseOfDylan.
Alexis Johnson
MD candidate, OS Survivor
University of Arizona College of Medicine Tucson
MIB Agents Board of Directors

Alexis Johnson is a 14-year Osteosarcoma Cancer survivor and an amputee. During her treatment, she spent countless hours in the hospital and became close with the patients around her. It was here that she met some of the most incredible children who never let their illness stand in their way. She watched them bravely battle osteosarcoma and many losing their fight due to exhausting all treatment options. When Alexis learned that there has been no new treatments and not enough research done, this drove Alexis to wanting to do something to help change this outcome. This led to Alexis dedicating her life to becoming an advocate in the fight against Osteosarcoma. She joined the MIB Agents program several years ago and has worked on several initiatives with them. Alexis is currently in her fourth year of medical school at the University of Arizona with an end goal of becoming a pediatric oncologist. Alexis grew up in San Diego, and has a huge support system of 5 brothers and sisters and family.

Rosandra (Rosie) Kaplan, MD
Senior Investigator Physician Scientist
Pediatric Oncologist
National Cancer Institute
MIB Agents Scientific Advisory Board

Dr. Kaplan is a physician scientist who developed the concept of the pre-metastatic niche describing the changes in distant microenvironments in response to a growing tumor that create a niche environment conducive to disseminating tumor cell survival and growth resulting in clinically relevant metastasis. Dr Kaplan has an active translational research program focusing on developing novel biomarkers and targets of the metastatic microenvironment by understanding the commonalities in mechanisms employed by a cancer cell to generate an entire heterogenous tumor at distant sites and stem cells and their niche to repopulate tissues.

Lori Krause
Grief Coach
The Hand Holders

To be of service to others during the most vulnerable times of their lives is my life's purpose. I am a life coach with a focus on grief as well as end of life. I have a deep passion for relationship building, open and honest communicating; healing; loving; and care giving. I believe every person has the desire to feel like they matter, feel supported, and heard. My own experiences of living with someone with chronic illness; the death of my husband at a young age; the sudden loss of my father; my grandmother's suicide; the death of several friends; the inability to have children; a move across the country; the loss of a business; and the loss of my fur baby have taught me much about life, love, loss, and grief. Each of these experiences transformed me and is what makes me passionate about walking the healing journey of loss with my clients. I believe every person should feel safe, supported, and guided through their grief and at the end of life. My approach is to “hold hands” and walk alongside my clients as they process life’s deep emotions, loss, and challenges. I create a compassionate, supportive space; provide education on what is normal/healthy in grief and mourning; help discover coping tools; help find new perspectives, and create hope for the future. I am a hospice-trained grief facilitator for both adults and children. I am an INELDA-trained End of Life Doula; I have completed the Accredited Coach Training Program and am close to attaining my professional coaching credential (PCC) with the ICF as an End of Life and Grief Coach.

“Avoid the support of MIB Agents, this type of work just would not get done. Simply put.”
– Matteo Trucco, MD

John Ligon, MD
Assistant Professor
University of Florida

Dr. Ligon completed his Pediatrics residency at UT Southwestern and then did his Pediatric Hematology/Oncology fellowship at the Johns Hopkins/NCI combined training program, which he completed in 2019. He then stayed at Hopkins for a year as a Sarcoma fellowship, and spent a year at the NCI where he was closely involved in several early phase clinical trials for immunotherapeutics in pediatric cancer. He has now joined the faculty at the University of Florida in January and will be closely collaborating with other investigators to move novel immunotherapeutics into early phase pediatric clinical trials.

Amanda Marinoff, MD
Pediatric Hematology/Oncology Fellow
University of California, San Francisco

Amanda Marinoff received her medical degree from Harvard Medical School and subsequently completed her residency in Pediatrics at Boston Children's Hospital. She is currently completing her fellowship in Pediatric Hematology-Oncology at University of California San Francisco, where she treats children, adolescents and young adults with cancers and hematologic disorders. Her research is focused on translational genomics and precision oncology, with the goals of identifying prognostic biomarkers and developing novel therapeutic strategies for pediatric patients with sarcomas.
Troy McEachron, PhD

Investigator
NIH/NCI/POB

Dr. McEachron earned his doctorate in Molecular and Cellular Pathology from the University of North Carolina at Chapel Hill in 2011. He completed postdoctoral fellowships at St. Jude Children's Research Hospital and at the Translational Genomics Research Institute. In 2016, Dr. McEachron joined the faculty of the Keck School of Medicine at the University of Southern California. As the Chair of the Voting Body of COG and a member of the Bone Sarcoma & Soft Tissue Sarcoma Steering Committees, Dr. McEachron has been an Associate Professor of Pediatrics at the Keck School of Medicine, University of Southern California. His research focus is on clinical trials for sarcomas in pediatrics, adolescents, and young adults, as well as developmental therapeutics for pediatric solid tumors.

Corrie Painter, PhD

Deputy Director
Broad Institute of MIT Count Me In

Corrie Painter is the Deputy Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focusing on melanoma. In 2010, Painter was diagnosed with angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies with a focus in angiosarcoma, osteosarcoma and leiomyosarcoma. She is also the co-founder of Angiosarcoma Awareness Inc.

Emily Pope

DVM/PhD Candidate
University of Minnesota

Emily Pope is a dual DVM/PhD candidate at the University of Minnesota. In her research, Emily is interested in identifying the underlying drivers of chemotherapy resistance in metastatic osteosarcoma to improve patient outcomes in human and veterinary medicine. In particular, she is focused on understanding the role hyaluronan plays in preventing effective chemotherapy treatment of osteosarcoma lung metastases. Her PhD research also focuses on identifying novel genetic drivers of human cancers using Sleeping Beauty insertional mutagenesis screens. She has received multiple grants for her research and been awarded several national scholarships and fellowships, including the Dr. Jack Walther Leadership Award, the Al Weber DVM/PhD Fellowship, and the Zoetis Veterinary Student Scholarship.

Leo Mascarenhas, MD, MS

Deputy Director, Cancer & Blood Disease Institute, Section Head-Oncology, Director, Sarcoma & Solid Tumor Program
Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California

Leo Mascarenhas, MD, MS is the Deputy Director of the Cancer & Blood Disease Institute, & Section Head of Oncology within the Division of Hematology/Oncology at Children's Hospital Los Angeles (CHLA). He is also the Director of the Sarcoma & Solid Tumor Program, the Director of the Early Phase Clinical Trials Program, & the Principal Investigator for the Children's Oncology Group (COG) at CHLA. As the Chair of the Voting Body of COG & a member of the Bone Sarcoma & Soft Tissue Sarcoma Steering Committees, Dr. Mascarenhas is an Associate Professor of Pediatrics at the Keck School of Medicine, University of Southern California. His research is focused on clinical trials for sarcomas in pediatrics, adolescents, and young adults, as well as developmental therapeutics for pediatric solid tumors.

Nicola Mason, PhD, BVetMed

Professor of Medicine & Pathobiology
University of Pennsylvania

Nicola Mason is a Professor in the Department of Clinical Sciences and Advanced Medicine at the University of Pennsylvania's School of Veterinary Medicine. She received her veterinary degree from the Royal Veterinary College and her Immunology PhD from the University of Pennsylvania. She performed her post-doctoral fellowship at the Abramson Cancer Center at the School of Medicine at UPenn.

Dr. Mason’s translational research focuses on developing safe and effective immunotherapies for dogs with cancer. Through comparative medicine her work aims to accelerate the clinical implementation of effective immunotherapies into the human clinics. Dr. Mason leads the first canine cancer immunotherapy consortium, supported by the Biden Cancer Moonshot initiative. She is the principal investigator of the national study, performed through the Comparative Oncology Trials Consortium, to evaluate the effects of a live, recombinant HER2 targeting Listeria vaccine in dogs with osteosarcoma.

“When we look at projects that are focused on osteosarcoma, this funding has been critical to the work we have already done, and is the reason this project will get done. This work was not going to be able to move forward without the support of MIB Agents. I am incredibly grateful.”
– J. Andrew Livingston, MD
Scott Sauer, PhD  
Head of Preclinical Discovery  
Vuja De Sciences  

Dr. Sauer is a passionate and innovative scientist with extensive research expertise and a dedication to Making it Better for all OS patients. Scott's multidisciplinary training in the fields of cancer biology, immunotherapy and organic chemistry provides a unique perspective to tackle difficult biological problems and unmet medical needs, such as preventing OS recurrence – the primary focus of his work at Vuja De. Dr. Sauer received his postdoctoral training at Duke University (2011-2016), primarily in cancer biology focusing on mechanisms of therapeutic resistance and disease progression. During this time, Scott received numerous postdoctoral awards including his work on the interplay between cancer progression and environmental toxicants. Scott received his PhD at Duke University in organic chemistry in 2011 and a BS from the University of Maryland, Baltimore County (UMBC) in 2005.

Emily Rav, DO  
Pediatric Hematology-Oncology Fellow  
University of Texas MD Anderson Cancer Center  

Emily is a Pediatric Hematology-Oncology fellow with clinical expertise. She studies CD70 chimeric antigen receptor (CAR) NK cells as direct targets to Osteosarcoma and uses novel imaging tools to track NK cells. Her goal is to generate the preclinical studies that will support the development of a clinical trial. In addition, she oversees and contributes to the development and maintenance of the Pediatric Biorepository clinical database.

C. Patrick Reynolds, MD, PhD  
Cancer Center Director  
Cancer Center Texas Tech University Health Sciences Center  
School of Medicine  

Dr. Reynolds is the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center. His research focuses cancer developmental therapeutics and he pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma. Other research interests include mechanisms of resistance to drugs and antibody therapy in childhood and adult cancers, biobanking of human cancers, and development of novel preclinical testing systems for cancer drug development. His most recent research focuses on use of telomere maintenance mechanisms as prognostic markers and developing agents to specifically target alternate telomere lengthening (ALT) cancers. He has sponsored multiple investigational New Drug (IND) applications with the FDA and receives grant funding from the NIH, DOD, ALSF, and CPRIT.

Lisl Schweers, LCSW, OSW-C  
Clinical Social Worker  
Children's Hospital Los Angeles  

Lisl is the clinical social worker for the LIFE Cancer Survivorship & Transition Service in the Cancer and Blood Disease Institute at Children's Hospital Los Angeles. Ms. Schweers’ clinical interests include the incorporation of mindfulness-based practices into the psychosocial care of cancer survivors, healthcare transitions, and teaching advocacy skills to patients and families. Ms. Schweers recently served on the board of directors of the Association of Pediatric Oncology Social Workers as the Legal and Advocacy Chair. She is on the Professional Advisory Board for the Cancer Support Community Los Angeles, and is a member of the Society for Social Work Leadership in Healthcare and the Association of Oncology Social Workers. Ms. Schweers received her Bachelor of Arts degree in International Studies from Southwestern University and her Master of Science in Social Work degree from the University of Texas at Arlington.

Ryan Roberts, MD, PhD  
Principal Investigator  
Nationwide Children’s Hospital  

Ryan Roberts, MD, PhD, is a physician in the Division of Hematology, Oncology and Blood and Marrow Transplant at Nationwide Children’s Hospital and a principal investigator in the Center for Childhood Cancer and Blood Diseases at the Abigail Wexner Research Institute at Nationwide Children’s. Dr. Roberts is an assistant professor of pediatrics and a member of the Translational Therapeutics research program at The Ohio State University James Comprehensive Cancer Center. He is a graduate of the Medical Scientist Training Program at The Ohio State University College of Medicine. He completed his residency in pediatrics and a Pediatric Hematology, Oncology and BMT fellowship at Nationwide Children’s. A physician-scientist, Dr. Roberts specializes in treating childhood sarcomas. He has led the Osteosarcoma Biology Committee of the Children’s Oncology Group since 2020. The Roberts Laboratory studies the processes that lead to metastasis in osteosarcoma and other pediatric solid tumors.

Learn more about WARRIOR MAIL  
www.MIBagents.org  

“We are in-patient for pain control, but Taily was able to open the Warrior Mail this evening. Please know that it makes her super happy to know that you all think about her.”  
– Daisy, Mother of Taily.
Elizabeth Stewart, MD
Assistant Member, Solid Tumor Division
St. Jude Children's Research Hospital

Dr. Stewart is a physician scientist and her research program is focused on understanding the molecular and cellular mechanisms of disease recurrence of pediatric sarcomas. Her overall goal is to bridge the gap between the laboratory and the clinic and move promising new therapeutic combinations forward into clinical trials. She spends 80% of her time leading a laboratory-based effort in pediatric solid tumor translational research and 20% of her time engaged in clinical care of high-risk sarcoma patients. In order to better understand the biology of pediatric sarcomas, she has been utilizing advanced preclinical modeling systems and has generated over 300 patient-derived orthotopic xenografts. These models are fully characterized and made freely available to the scientific community through the Childhood Solid Tumor Network.

Eric Alejandro Sweet-Cordero, MD
Chief of the Division of Oncology in the Department of Pediatrics
UCSF

Dr. Sweet-Cordero is a cancer biologist and practicing pediatric oncologist focused on basic and translational cancer research. His laboratory's disease focus includes both pediatric sarcomas and lung cancer. Their sarcoma work is focused on defining mechanisms driving osteosarcoma and Ewing sarcoma progression, metastasis and therapy resistance. They have extensive expertise in integrative genomic analysis (WGS, RNAseq, ATACseq) and functional genomic studies using CRISPR/CAS9. Using tools to drive gene and network discovery using primary tumors, patient-derived xenograft models, and genetically engineered mouse models. He also has experience in real-world application of tumor sequencing for precision cancer medicine and is currently the lead for the Molecular Oncology Initiative (MOI) at UCSF.

Kara Skrubis
Junior Advisory Board President
MIB Agents

Kara was diagnosed with OS in 1/2020. She received 9 months of chemotherapy, a left above the knee amputation, and then 8 months of immunotherapy. Currently, she is 21 years old, living in Buffalo, New York and attending the University at Buffalo pursuing her child life certification. In her free time she enjoys dancing, art, fostering dogs, photography, and her work with the MIB Junior Advisory Board serving as the 2022 president.

Kara Skrubis
Junior Advisory Board President
MIB Agents

Kara was diagnosed with OS in 1/2020. She received 9 months of chemotherapy, a left above the knee amputation, and then 8 months of immunotherapy. Currently, she is 21 years old, living in Buffalo, New York and attending the University at Buffalo pursuing her child life certification. In her free time she enjoys dancing, art, fostering dogs, photography, and her work with the MIB Junior Advisory Board serving as the 2022 president.

Bhuvana Setty, MD
Associate Professor of Pediatrics
Nationwide Childrens Hospital

Dr. Bhuvana Setty is an Associate Professor of Clinical Pediatrics at The Ohio State University with a dual appointment in the Division of Pediatric Hematology, Oncology, and the Pediatric Blood and Marrow Transplant Program at Nationwide Children’s Hospital. She is also the Director of the Sarcoma Program, Co-Physician Lead in both the Lymphatic Imaging and Interventions Program and the Hemangioma and Vascular Malformations Clinic, all at Nationwide Children’s Hospital. Dr. Setty has served as a principal investigator for multiple studies, has over a decade's experience in research, and has published over 30 articles and book chapters. She is the PI of the upcoming clinical trial utilizing Natural Killer Cells in addition to chemotherapy for patients with relapsed sarcoma.

Michelle Sexton, ND
Naturopathic Doctor
UCSD

Dr. Sexton is a Naturopathic Doctor graduated from Bastyr University in Seattle, WA. She completed fellowships at the University of Washington. Her NIH-funded pre-doctoral and postdoctoral research on the topic of cannabinoids and their roles in neuroinflammation and neurodegeneration. She has continued research into health effects of cannabis at UCSD currently affiliated with the Center for Integrative Health at UCSD. Dr. Sexton's clinical practice, research and teaching focus on the endocannabinoid system and roles in integrative medicine, across the lifespan. Dr. Sexton has presented her research internationally and published 24 papers in peer-reviewed journals. She is a member of the International Cannabinoid Research Society, the International Association of Cannabinoid Medicine and the American Association of Naturopathic Doctors. She maintains a private medical practice in San Diego, CA.

Pradeep Shrestha, PhD
Postdoctoral Fellow
The University of Texas MD Anderson Cancer Center

Pradeep Shrestha, Ph.D is an Odyssey Fellow and works under the mentorship of Dr. Eugenie Kleinerman at Department of Pediatrics-Research, the UT MD Anderson Cancer Center. He holds MS and Ph.D degrees in Microbiology and Immunology from the University of Louisville, where he investigated novel approaches to modulate immune microenvironment for the treatment of immunologic disorders including, Type-1 Diabetes and graft-versus host disease. He is currently researching multiple immune therapeutic strategies to activate and promote immune responses for the prevention and treatment of osteosarcoma lung metastasis.
Dr. Terezakis earned her MD at Johns Hopkins School of Medicine and went on to complete her residency, which she served as Chief Resident, in radiation oncology at MSKCC. She joined the faculty at Johns Hopkins School of Medicine specializing in pediatric radiation oncology with a focus on soft tissue and bone sarcomas. While at Johns Hopkins, she served as both the Residency Program Director and Director of Clinical Operations working to develop the Johns Hopkins Proton Therapy Center. She became the Vice Chair of Research at the University of Minnesota Department of Radiation Oncology in 2019 and subsequently became Chair of the Department in 2020. Terezakis focuses her clinical practice on pediatric cancers and musculoskeletal tumors. Her clinical and translational research incorporates advanced diagnostic radiology techniques into the radiation treatment planning of cancers to minimize long-term side effects and improve efficacy of treatment. She is also an active investigator of stereotactic body radiation therapy in pediatric and adult tumors. Dr. Terezakis is a leader within the Children’s Oncology Group where she is a member of the soft tissue sarcoma steering committee. She is also a member of multiple national committees that establish the standard of care for pediatric cancer treatment.

Dr. Matteo Trucco is a Pediatric Oncologist at the Cleveland Clinic specializing in the treatment of sarcomas. He is also the Director of the Children’s Cancer Innovative Therapy Program and Clinical Director and Quality Improvement Officer for the Department of Pediatric Hematology-Oncology & BMT. He joined the Cleveland Clinic in November 2019 and develops clinical trials both locally and in collaboration with national consortia and pharmaceutical companies to identify new and less toxic treatments for children with cancer. He has had the honor of collaborating with MIB Agents since 2016 helping to identify new and less toxic treatments for children with cancer. He also serves as an active investigator of stereotactic body radiation therapy in pediatric and adult tumors.

Dr. Kristen VanHeyst received her medical degree from New York College of Osteopathic Medicine. She followed this with a pediatric residency at Stony Brook Children’s Hospital in Stony Brook, NY where she remained for an additional year to serve as Chief Resident. Dr. VanHeyst completed her Pediatric Hematology/Oncology fellowship in 2019 at University Hospitals/Rainbow Babies and Children’s Hospital in Cleveland, OH. As a fellow, Dr. VanHeyst joined Dr. Alex Huang's laboratory with a primary interest in metastatic osteosarcoma and a desire to become a translational therapeutics-oriented clinical physician-scientist. She was appointed as an Assistant Professor of Pediatrics at Case Western Reserve University School of Medicine in 2019. Dr. VanHeyst continues her research efforts in understanding the role of the tumor microenvironment in osteosarcoma. She is now the PI of a Phase II investigator initiated trial at her institution. She is also the recipient of an NIH K12 award.

Dr. Olena Vaske is the Founder of the Treehouse Childhood Cancer Initiative at the University of Santa Cruz Genomics Institute, where she is Assistant Professor of Molecular, Cell and Developmental Biology. Dr. Vaske is the scientific lead for the California Kids Cancer Comparison (CKCC) project, one of the demonstration projects of the California Initiative to Advance Precision Medicine, a public-private effort recently launched by Governor Edmund G. Brown, Jr. Dr. Vaske’s research focuses on developing novel RNA-Seq analysis approaches to discover druggable targets for pediatric cancer patients. Dr. Vaske holds a PhD in Bioinformatics from the University of British Columbia and a BSc (Hons) in Molecular Genetics and Biology from the University of Toronto.
Betsy Young, MD
Clinical Fellow
UCSF Benioff Children's Hospital

Betsy Young is a physician-scientist and a pediatric hematology/oncology specialist, who intends to advance the field of pediatric oncology by pursuing a research career focused on developing novel immuno-oncology approaches to target pediatric sarcomas. Betsy is investigating the pathogenesis of osteosarcoma metastasis in the Sweet-Cordero lab at UCSF, with a specific focus on immuno-oncology that is strengthened by multiple collaborations at UCSF and Stanford. Clinically, her area of expertise is pediatric sarcoma, and she is a member of the UCSF Pediatric Solid Tumor group. The paucity of novel therapeutic options and adverse outcomes of her patients with osteosarcoma have crystallized for her a personal calling to advance our understanding of this pediatric cancer in her own career as a physician scientist. Outside of Young's passion for osteosarcoma research, she enjoys traveling with her husband, running, pickling vegetables, and spending time with her two cats.

Stacey Zahler, DO
Clinical Assistant Professor, Department of Pediatric Hematology, Oncology, & Blood & Marrow Transplantation
Cleveland Clinic Children's

Dr. Zahler is a pediatric oncologist specializing in pediatric solid tumors at Cleveland Clinic Children's. She trained at Maria Fareri Children's Hospital in Westchester, NY. Current research interest is in the epigenomic differences between pre- and post-treatment in rhabdomyosarcoma, and she has educational roles as the associate director of the medical student clerkship at Case Western Reserve University & Cleveland Clinic Lerner College of Medicine, and incoming program director for the Pediatric Hematology/Oncology Fellowship program.

You can also view the Agenda and Speakers List by visiting: www.MIBagents.swoogo.com/factor2022/
WE CAN'T MAKE IT BETTER WITHOUT YOU.

Please consider a gift today that will support those facing osteosarcoma.
WITH HEARTFELT APPRECIATION

What most businesses and organizations call “sponsors”, we call “partners” and “friends”. We absolutely cannot deliver this conference, scientific & patient programs, education, and research without the people and companies you have been hearing and reading about in this program and at this conference like BTG Pharmaceutical and OS Institute. As we have said since the first FACTOR, “The pursuit of a worthy goal requires the hearts and hands of many.” How deeply grateful we are to our partners and friends who Make It Better. Here are some friends of MIB we are grateful for...

THE JEFFRIES FAMILY
The Jeffries Family contributes greatly to MIB Agents all year long and to the FACTOR Conference annually. Gigi serves on the MIB Agents Board of Directors, has been the OsteoWarriors HQ Chief for three years, and a consultant the past two years. Because of Gigi and the entire Jeffries Family, the OsteoWarriors Headquarters (HQ) continues to create joy, connection and belonging for our warriors.

THE VAN SCOTT FAMILY
There are Special Agents among us, and they are the Van Scotts. They Make It Better every single day for MIB Agents and the missions we undertake. We have the confidence to move forward with various initiatives, great and small because of their support. How incredibly grateful we are to them for their trust, friendship, and support in our mission.

THE JOHNSON & NULTY FAMILIES & TED NULTY SECURITY
This family has supported MIB Agents in many ways; auction items, rallying family & friends, volunteering and so much more. This year, Ted Nulty Security helped make travel to FACTOR attainable for a Junior Advisory Board member and elevated our Speaker Dinner. Their kind support truly Makes It Better.

THE HESS FAMILY
We are grateful for the ongoing and meaningful support of the Hess Family. It is always a good idea to have friends who appreciate beer & tacos; it’s even better when those people use their powers for good to Make It Better for kids with osteosarcoma. To be the beneficiary of their generosity allows us to positively impact those who suffer.

730 EDDY
No doubt you have (or will shortly) come across the video team who are our “ride or die”. They, like all really great friends, care about what you care about, show up, and meaningfully improve the space they are in. Andy & Team produce OsteoBites each week, ride shotgun on our travels to capture our community’s stories, and do it all with an engaged and delightful presence.

COMMANDER MOHAN ANAND
Mohan passed from osteosarcoma after a battle he silently fought while Project Manager for the FACTOR 2017. Mohan is a part of every conference. We honor him annually - in this program and with our signature “Mohanito” at each Welcome Reception. Mohan joined our first FACTOR via FaceTime in 2017 from his hospital bed. He passed away a few days later. He is greatly missed by MIB Agents, his family, and friends.

Matteo Trucco, MD
Co-Chair (Science)

Ann Graham
Co-Chair (Operations)

Sarah Goobic
Registration & Tech

Randi Bartles
Registration

Briana Paronto
Printed Program Design

Linda Kennington
Photography, Luminaria, Ribbons

Christina Ip-Toma
Scientific Program

Rob Marsh
Floor Manager

Anita Caldera
Event Planner

Anna Eggleton
Marketing, Speaker Gifts, Angel Wall, Website, Social Media

Sean Brosnan
Gamer Agents HQ Lead

Mary O’Hannigan
HQ Chief

Isabel Wolf
Ambassador Agent Training

Serena & Mia Sandino
Wellness Track

Rebecca Rogers
Onsite Welcome & Registration

Vanessa Valenti
Check in/Volunteer Coordinator, Transportation Guide

Joey Cristo
Runner/Transport

Joe O’Hannigan
Runner/Transport

Mark Atkins
Floral & Events

John Graham
Operations

Jim & Vickie Reilly
Caretakers of FACTOR Shipments

Teri-Gene Conlin
Partnerships & Family Funds
BTG Is Proud to Sponsor MIB Agents

Collaborating to Make It Better
for the pediatric osteosarcoma community of patients, caregivers, doctors, and researchers

MIB FACTOR
OSTEOSARCOMA CONFERENCE
June 23-25 2022
in person/hybrid

San Diego, California